Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

58.18 -4.29 (-6.87%)
Streaming Delayed Price Updated: 1:21 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
The holds are temporary while the teenager's death is under investigation. 
Via Investor's Business Daily
Topics Death
Exposures Death
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
Via Benzinga
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
8 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price... 
Via StockStory
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
Exposures Product Safety
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Via The Motley Fool
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case. 
Via Stocktwits
Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday?
Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York. 
Via Benzinga
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with... 
Via StockStory
Discover the top movers in Tuesday's pre-market session.
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor. 
Via Benzinga
Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies
The patient also had a recent CMV infection, which the company said could have contributed. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting. 
Via Benzinga
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was... 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.